tetano
Editor, Senior Moderator
Curr Opin Gastroenterol
. 2022 Sep 1;38(5):443-449.
doi: 10.1097/MOG.0000000000000859.
Upper gastrointestinal bleeding in coronavirus disease 2019 patients
Aurelio Mauro[SUP] 1 2 [/SUP], Federico De Grazia[SUP] 2 [/SUP], Andrea Anderloni[SUP] 2 [/SUP], Antonio Di Sabatino[SUP] 1 [/SUP]
Affiliations
Abstract
Purpose of review: Upper gastrointestinal bleeding (UGIB) has significant morbidity and UGIB cases have been described in coronavirus disease 2019 (COVID-19) patients. Management of this condition can be challenging considering both the possible severe COVID-19-related pneumonia as well as the risk of the virus spreading from patients to health operators. The aim of this paper is to review the most recent studies available in the literature in order to evaluate the actual incidence of UGIB, its clinical and endoscopic manifestations and its optimal management.
Recent findings: UGIB has an incidence between 0.5% and 1.9% among COVID-19 patients, and it typically presents with melena or hematemesis. Peptic ulcers are the most common endoscopic findings. High Charlson Comorbidity Index (CCI), dialysis, acute kidney injury and advanced oncological disease increase the risk for UGIB. Although anticoagulants are commonly used in COVID-19 patients they are not associated with an increased incidence of UGIB. Conservative management is a common approach that results in similar outcomes compared to upper GI endoscopic treatment. Apparently, UGIB in COVID-19 seems not have a detrimental effect and only one study showed an increased mortality in those who developed UGIB during hospitalization.
Summary: Incidence of UGIB in COVID-19 patients is similar to that of the general population. Despite the widespread use of anticoagulants in these patients, they are not associated with an increased risk of UGIB. Conservative management could be an effective option, especially for patients that are at risk of intubation.
. 2022 Sep 1;38(5):443-449.
doi: 10.1097/MOG.0000000000000859.
Upper gastrointestinal bleeding in coronavirus disease 2019 patients
Aurelio Mauro[SUP] 1 2 [/SUP], Federico De Grazia[SUP] 2 [/SUP], Andrea Anderloni[SUP] 2 [/SUP], Antonio Di Sabatino[SUP] 1 [/SUP]
Affiliations
- PMID: 35916320
- DOI: 10.1097/MOG.0000000000000859
Abstract
Purpose of review: Upper gastrointestinal bleeding (UGIB) has significant morbidity and UGIB cases have been described in coronavirus disease 2019 (COVID-19) patients. Management of this condition can be challenging considering both the possible severe COVID-19-related pneumonia as well as the risk of the virus spreading from patients to health operators. The aim of this paper is to review the most recent studies available in the literature in order to evaluate the actual incidence of UGIB, its clinical and endoscopic manifestations and its optimal management.
Recent findings: UGIB has an incidence between 0.5% and 1.9% among COVID-19 patients, and it typically presents with melena or hematemesis. Peptic ulcers are the most common endoscopic findings. High Charlson Comorbidity Index (CCI), dialysis, acute kidney injury and advanced oncological disease increase the risk for UGIB. Although anticoagulants are commonly used in COVID-19 patients they are not associated with an increased incidence of UGIB. Conservative management is a common approach that results in similar outcomes compared to upper GI endoscopic treatment. Apparently, UGIB in COVID-19 seems not have a detrimental effect and only one study showed an increased mortality in those who developed UGIB during hospitalization.
Summary: Incidence of UGIB in COVID-19 patients is similar to that of the general population. Despite the widespread use of anticoagulants in these patients, they are not associated with an increased risk of UGIB. Conservative management could be an effective option, especially for patients that are at risk of intubation.